Abstract
Background Asthma, a chronic inflammatory airway disorder, can increase the risk of hospitalizations in individuals with viral infections such as COVID-19. The impact of the COVID-19 pandemic on asthma-related hospitalizations in the United States remains unknown.
Objective We hypothesized that the COVID-19 pandemic led to an increase in economic burden to society and a decrease in hospitalization rates for asthma.
Methods We analyzed weighted data from National Inpatient Sample (NIS) between January 1, 2018, and December 31, 2020. The outcomes were asthma hospitalization rates, length of stay (LOS), in-hospital mortality rates, and hospital admission costs.
Results More people were admitted with a primary diagnosis of asthma in 2018 and 2019 compared to 2020 (hospitalization rate per 100,000: 2018: 38.6 versus (vs) 2019:37.0 vs 2020: 21.4; P <0.001). Hospital costs increased (2018: median [IQR] 5,251 [ 3,426, 8,278]; 2019:5,677 [3,725, 8.969]; 2020: 5,881 [3,920-9,216]; P <0.001). Additionally, in-patient mortality rates slightly increased in 2020, rising to 0.44%, compared to 0.20% in 2018 and 0.30% in 2019 (P <0.001). When comparing geographic divisions, the mid-Atlantic division had the highest hospitalization rates, and the Pacific division had the highest hospitalization costs from 2018-2020 (P <0.05).
Conclusion Asthma hospitalizations decreased in 2020 compared to previous years. Those admitted during the pandemic had slightly higher mortality and significantly increased hospital costs. This investigation provides valuable insights for policy makers about shifts in healthcare utilization during the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by Cleveland Clinic Research Program Committee.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data is found at HCUP-NIS: https://hcup-us.ahrq.gov/nisoverview.jsp.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- AHRQ
- Agency for Healthcare Research and Quality
- APR-DRG
- All Patient Refined Diagnosis Related Group
- CCR
- Cost-To-Charge Ratios
- COPD
- Chronic Obstructive Pulmonary Disease
- ED
- Emergency Department
- HCUP
- Healthcare Cost and Utilization Project
- NIS
- National Inpatient Sample
- US
- United States
- USD
- United States Dollars
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.